BG Medicine announces plans to conduct public sale of its common stock

Bookrunner Lazard Capital Markets helps raise proceeds for operations

By Devika Patel

Knoxville, Tenn., April 2 - BG Medicine, Inc. plans to price a public offering of stock with a 30-day greenshoe, according to a preliminary prospectus supplement filed Wednesday with the Securities and Exchange Commission.

Lazard Capital Markets LLC is the sole bookrunning manager.

Proceeds will be used for operations, including advancing the commercialization of the company's cardiovascular diagnostic tests in the United States and Europe and developing new clinical claims; to expand the company's product pipeline and for other general corporate purposes, including capital expenditures, licensing of intellectual property, debt repayment and working capital.

BG Medicine is a Waltham, Mass., life sciences company focused on biomarker-based cardiovascular diagnostics.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.